UNSPSC 41116000: Clinical and diagnostic analyzer reagents

UNSPSC 41116000 Clinical and diagnostic analyzer reagents is a Class code. State and local governments purchase diagnostic testing supplies under this code, including FDA-approved confirmatory assay systems, microorganism detection reagents, water quality testing kits, and laboratory analyzer components. The Florida Department of Health Bureau of Public Health Laboratories and the Texas Health and Human Services Commission represent the typical issuing bodies—state health departments and regional laboratory facilities—though universities with clinical research programs also solicit under this code. Recent opportunities reflect a narrow, specialized market: the Florida Department of Health is procuring Bio-Rad Laboratories Geenius System assays and controls for HIV-1/HIV-2 confirmation at an estimated $460,000 under sole-source justification (the system is the only FDA-approved differential assay validated for oral fluid testing); Texas HHSC is requesting bids for IDEXX COLILERT reagents and water bottles for bacteriological testing at South Texas Laboratory, with historical annual spend of $70,050 to $90,000 and a firm fixed-price requirement for September 2026 through August 2027 plus four optional renewals.

Recent activity concentrates in Florida and Texas, with sole-source and competitive procurements reflecting both the specialized nature of diagnostic chemistry and the regulatory lock-in created by FDA approval and in-house validation. The code sees limited volume and frequency—the identifiable opportunities in the past three months include two Bio-Rad sole-sources (one posted June 15, reposted July 9 with identical scope at $460,000), the Texas COLILERT requirement, and no other state or local solicitations by major issuing bodies. Geographic spread is sparse; no secondary states show activity in the recent block. Pursuit of this code requires deep FDA and laboratory accreditation expertise, established distribution relationships with manufacturers like Bio-Rad and IDEXX, and the ability to support sole-source procurement justifications in highly regulated clinical settings where switching costs and validation timelines create durable incumbent positions.